Viridian Pharma - רווח נקי למניה אחת בשנים עשר החודשים האחרונים VRDN

Viridian Therapeutics (VRDN) relies on the development of antibodies for eye and thyroid therapies, reducing long-term risks. The EPS YoY growth rate (trailing 12 months) visualizes this trend, where the level of -18.10 is the current value. The company's developments make the treatment of ophthalmopathies safer, and the transition to subcutaneous injections is aggressively disrupting established intravenous therapy standards.
VRDN (Viridian Therapeutics): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To isolate fundamental stability from market noise, it is necessary to analyze the year-over-year dynamics of net earnings per share over the last twelve months. By analyzing the EPS YoY growth rate (trailing 12 months), an investor assesses profit generation efficiency, which is critical for Viridian Therapeutics (VRDN) due to high R&D capital burn and a lack of regular commercial revenue.